Toronto Stock Exchange Symbol: MS
EDMONTON, Aug. 12 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and operational results for the second quarter ended June 30, 2008. BioMS Medical, in partnership with Eli Lilly and Company (Lilly), is developing MBP8298 (dirucotide), a drug for the treatment of MS undergoing pivotal trials in Canada, Europe and the US.
"The three randomized late-stage clinical trials for MBP8298 (dirucotide) continue to progress very well. We recently announced that MAESTRO-03, our U.S. phase III secondary progressive MS trial, was fully recruited with approximately 510 patients," said Kevin Giese, President and CEO of BioMS Medical. "During the quarter, BioMS was also honored to receive the Gold Leaf Award from BIOTECanada in recognition of our selection as "Company of the Year".
Currently, BioMS is conducting three clinical trials and one open-label follow-on trial for MBP8298 (dirucotide):
(x) MAESTRO-01: A randomized, double-blind pivotal phase II/III trial in Canada and Europe evaluating MBP8298 (dirucotide) for the treatment of secondary progressive MS (SPMS). The study has completed full recruitment of 611 patients at 47 trial sites in 10 countries. Patients are administered either MBP8298 (dirucotide) or placebo every six months for a period of two years. To date, there have been eight positive safety reviews from the Data Safety Monitoring Board (DSMB).
(x) MAESTRO-02: An open-label follow-on study to the MAESTRO-01 pivotal trial. Eligible patients who have successfully completed the blinded, placebo controlled MAESTRO-01 trial may choose to receive MBP8298 (dirucotide) on an un-blinded basis. To date, approximately 95% of patients enrolled in MAESTRO-01 have proceeded to MAESTRO-02.
(x) MAESTRO-03: A U.S. pivotal phase III trial evaluating MBP8298
(dirucotide) for the treatme
|SOURCE BioMS Medical Corp.|
Copyright©2008 PR Newswire.
All rights reserved